This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citing articles on ISI (3)  • Contact me when this article is cited  Related Content  • Similar articles in JAMA

Charles Marwick

JAMA. 1999;282:315-316.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Washington—Reducing the number of adverse drug reactions in the United States will take a concerted effort on the part of everyone involved, not just pharmaceutical manufacturers and regulators but physicians, patients, policymakers, and health plan administrators. New direction and leadership at the highest level are needed if drug safety is to be ensured, said participants in a symposium on drug safety held here last month by the Center for Drug Development Science at Georgetown University Medical Center.

FDA'S RAISON D'ETRE

While concern about safe drugs and the proper use of medications is hardly new—it was the issue that resulted in the 1906 Food, Drug and Cosmetic Act—it has been heightened by recent reports of dire consequences of medication errors or inappropriate drug use.

This year, several US Food and Drug Administration (FDA) staff members published a review of the circumstances involving the removal of five drugs from . . . [Full Text of this Article]